Tags

Type your tag names separated by a space and hit enter

Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma.
Korean J Ophthalmol 2019; 33(3):228-237KJ

Abstract

PURPOSE

To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) treatment of eyes with foveal serous retinal detachment (SRD) associated with inferior staphyloma and to investigate choroidal thickness changes following anti-VEGF therapy.

METHODS

In this observational case series, eyes with inferior staphyloma accompanied by foveal SRD were treated with a single intravitreal anti-VEGF injection, followed by further injections as needed. Changes in height and width of subretinal fluid (SRF) and visual acuity after treatment were assessed. Choroidal thickness was measured at the subfovea, 1.5 mm superior and inferior to the fovea using enhanced depth imaging optical coherence tomography at baseline and 1 month after initial anti-VEGF therapy.

RESULTS

Six eyes from six patients were included. One month after the initial injection, the mean SRF height and width had decreased significantly from 112.5 ± 40.1 to 44.5 ± 48.7 μm (p = 0.046) and from 1,401.8 ± 627.3 to 690.7 ± 634.7 μm (p = 0.028), respectively. Mean choroidal thickness at the superior point decreased from 218.7 ± 59.3 to 200.5 ± 61.0 μm (p = 0.046). SRF resolved completely in three of the six eyes (50%) with a mean of 6.8 ± 5.9 injections (range, 1 to 15). All eyes experienced at least one recurrence of exudation, at a mean interval of 4.8 months. Mean visual acuity improvement was 0.17 logarithm of the minimum angle of resolution units at a mean of 28.7 months follow-up.

CONCLUSIONS

Anti-VEGF therapy resulted in an SRF decrease and modest visual improvement in eyes with foveal SRD associated with inferior staphyloma. Reduction in superior choroidal thickness appeared to contribute to the clinical improvements that were observed.

Authors+Show Affiliations

Department of Ophthalmology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea. Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. hgonyu@snu.ac.kr.

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

31179654

Citation

Lee, Eun Kyoung, and Hyeong Gon Yu. "Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated With Inferior Staphyloma." Korean Journal of Ophthalmology : KJO, vol. 33, no. 3, 2019, pp. 228-237.
Lee EK, Yu HG. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma. Korean J Ophthalmol. 2019;33(3):228-237.
Lee, E. K., & Yu, H. G. (2019). Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma. Korean Journal of Ophthalmology : KJO, 33(3), pp. 228-237. doi:10.3341/kjo.2018.0125.
Lee EK, Yu HG. Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated With Inferior Staphyloma. Korean J Ophthalmol. 2019;33(3):228-237. PubMed PMID: 31179654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcomes of Anti-vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma. AU - Lee,Eun Kyoung, AU - Yu,Hyeong Gon, PY - 2018/11/13/received PY - 2019/01/04/revised PY - 2019/01/12/accepted PY - 2019/6/11/entrez PY - 2019/6/11/pubmed PY - 2019/7/31/medline KW - Anti-vascular endothelial growth factor therapy KW - Choroidal thickness KW - Inferior staphyloma KW - Serous retinal detachment KW - Tilted disc syndrome SP - 228 EP - 237 JF - Korean journal of ophthalmology : KJO JO - Korean J Ophthalmol VL - 33 IS - 3 N2 - PURPOSE: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) treatment of eyes with foveal serous retinal detachment (SRD) associated with inferior staphyloma and to investigate choroidal thickness changes following anti-VEGF therapy. METHODS: In this observational case series, eyes with inferior staphyloma accompanied by foveal SRD were treated with a single intravitreal anti-VEGF injection, followed by further injections as needed. Changes in height and width of subretinal fluid (SRF) and visual acuity after treatment were assessed. Choroidal thickness was measured at the subfovea, 1.5 mm superior and inferior to the fovea using enhanced depth imaging optical coherence tomography at baseline and 1 month after initial anti-VEGF therapy. RESULTS: Six eyes from six patients were included. One month after the initial injection, the mean SRF height and width had decreased significantly from 112.5 ± 40.1 to 44.5 ± 48.7 μm (p = 0.046) and from 1,401.8 ± 627.3 to 690.7 ± 634.7 μm (p = 0.028), respectively. Mean choroidal thickness at the superior point decreased from 218.7 ± 59.3 to 200.5 ± 61.0 μm (p = 0.046). SRF resolved completely in three of the six eyes (50%) with a mean of 6.8 ± 5.9 injections (range, 1 to 15). All eyes experienced at least one recurrence of exudation, at a mean interval of 4.8 months. Mean visual acuity improvement was 0.17 logarithm of the minimum angle of resolution units at a mean of 28.7 months follow-up. CONCLUSIONS: Anti-VEGF therapy resulted in an SRF decrease and modest visual improvement in eyes with foveal SRD associated with inferior staphyloma. Reduction in superior choroidal thickness appeared to contribute to the clinical improvements that were observed. SN - 2092-9382 UR - https://www.unboundmedicine.com/medline/citation/31179654/Outcomes_of_Anti-vascular_Endothelial_Growth_Factor_Treatment_for_Foveal_Serous_Retinal_Detachment_Associated_with_Inferior_Staphyloma L2 - https://ekjo.org/DOIx.php?id=10.3341/kjo.2018.0125 DB - PRIME DP - Unbound Medicine ER -